HC Wainwright Increases Cognition Therapeutics (NASDAQ:CGTX) Price Target to $6.00

Cognition Therapeutics (NASDAQ:CGTX) had its target price upped by HC Wainwright from $5.00 to $6.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Chardan Capital reissued a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.30.

Cognition Therapeutics Stock Performance

Cognition Therapeutics stock opened at $0.63 on Thursday. The company has a market cap of $26.18 million, a P/E ratio of -0.65 and a beta of 1.26. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The business has a fifty day moving average of $0.48 and a two-hundred day moving average of $0.92.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Cognition Therapeutics in the 3rd quarter worth about $27,000. Mercer Global Advisors Inc. ADV raised its position in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after acquiring an additional 24,050 shares during the last quarter. Sigma Planning Corp raised its position in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after acquiring an additional 25,050 shares during the last quarter. Finally, CM Management LLC lifted its holdings in shares of Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.